Acclinate is a digital health company that leverages a unique combination of sustained community engagement and predictive analytics to improve health equity. Acclinate’s community platform helps pharmaceutical companies increase diversity in their clinical trials and other healthcare organizations support inclusivity in their initiatives.
Adela is developing best-in-class technology to accelerate the diagnosis and improve the management of cancer through blood tests for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). Adela’s genome-wide methylome enrichment platform, which utilizes the company’s patented cfMeDIP-seq platform, efficiently captures extensive, biologically-relevant genomic information to maximize test performance and improve treatment decisions.
AOA Dx is pioneering the field of Glycolipids, a new frontier in diagnostics. The proprietary biomarker technology in glycolipids detects early-stage cancer in blood by quantifying circulating gangliosides across multiple cancers and utilizing data science and AI to develop highly accurate diagnostic tests. AOA Dx is focused on women’s health with our first platform product detecting early-stage ovarian cancer, the deadliest gynecological cancer.
Biospectal democratizes blood pressure management at global scale by measuring and managing blood pressure via the fingertip on a smartphone camera. By completely virtualizing the blood pressure cuff into software on common smartphones, we enable convenient, connected, and ubiquitous access to monitoring – anytime, anywhere.
Circuit Clinical's mission is to make it easier for people to find, understand, and choose clinical research as a care option. The company helps study new medications, vaccines, digital health platforms, and medical devices while bringing research opportunities to doctors, medical practices, care organizations, and patients who might not otherwise be able to participate.
Droplet Biosciences is pioneering the use of lymphatic fluid collected from post-surgical drains as a source of unique and clinically relevant biomarkers to improve cancer patient care. 90% of cancers recur first via the lymphatic system, which makes it particularly relevant for identifying recurrence risk and enabling precision immuno-oncology.
Evvy is on a mission to close the gender health gap by discovering and leveraging female-specific biomarkers, starting with the vaginal microbiome. Evvy Vaginal Health Test is the first-ever at-home vaginal microbiome test to use metagenomic sequencing to tell you what’s up down there, why it matters, and what you can do about it. Simultaneously, Evvy is uncovering how female biomarkers can be better leveraged to diagnose, treat, and predict risk for complex health conditions in the female body.
Geneoscopy Inc. is a life sciences company focused on developing diagnostic tests for gastrointestinal health. Leveraging its proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform, Geneoscopy’s mission is to empower patients and providers to transform gastrointestinal health through innovative diagnostics.
Getlabs provides the infrastructure for delivering healthcare nationwide. Patients can book a Getlabs phlebotomist to draw their lab tests at their home or office. Providers can dispatch Getlabs' medical professionals to collect the diagnostic tests they need and make informed medical decisions remotely.
2019 Best in KLAS® population health management company with a single-platform solution aggregating clinical, claims, and quality data to provide actionable insights that improve health care outcomes and value-based care. HealthEC’s Oncology Care Module helps providers improve clinical/financial performance by monitoring treatment protocols and developing targeted therapies.
Mercy BioAnalytics is on a mission to save lives and relieve suffering through the early detection of cancer. Through the measurement of co-localized biomarkers found on tumor-derived extracellular vesicles present at high abundance in blood, the Mercy Halo test portfolio aims to detect cancer at its earliest stages, when it is most treatable.
Navigating Cancer is the leading Patient Relationship Management technology and solutions company focused on improving the patient experience, delivering more effective care management, and enabling oncology care innovation. With over 1,700 providers adopting the Navigating Care platform, it is the most deployed patient management solution in oncology.
NOWDiagnostics (NOWDx) develops and manufactures “Touch to Test” over-the-counter and point of care diagnostic tests that yield results in minutes. Its patented approach allows for virtually any immunological assay to be accurately performed in one step using a tiny amount of capillary blood or saliva. NOWDx envisions a world where people have greater access to in-home testing with in-home results - in minutes. We are committed to changing healthcare by providing accessible, affordable, and accurate testing for all.
Outcomes4Me is an AI-driven patient empowerment platform that helps cancer patients take a proactive approach to their care, gaining access to personalized, evidence-based treatment options and information. The company is on a mission to democratize healthcare by providing real-time, evidence-based clinical information to cancer patients, ensuring they can effectively navigate through their disease and improve their outcomes.
Perthera.ai uses the power of multi-omic cancer profiling and the advanced analytics of our proprietary Precision Oncology Platform to enhance oncologists' decision-making by providing a Perthera Report with matched and ranked therapy options, including clinical trials. Perthera.ai then collects and uses patient outcomes to continually inform and refine the process, ensuring that patients get access to the best available personalized therapy options for their cancer at any point in their journey.
Percipio Health is an end-to-end AI-guided platform for scalable, low-cost population health monitoring. Percipio provides device-free daily patient health monitoring via smartphone to inform a whole-person view of health that providers and payers use to proactively identify health risks, drive earlier discovery of undiagnosed conditions, and guide clinical diagnosis and treatment with next best actions.
Phenomix Sciences is a precision obesity biotechnology company on a mission to conquer obesity with proprietary genetic tests, unique data sets and advanced analytics. Phenomix leverages data intelligence to better predict individual patient response to specific weight loss interventions, reducing variability in weight loss. The company’s MyPhenome® test identifies sub-types, or phenotypes, of obesity, helping physicians guide patient treatment.
Presage Biosciences uses its proprietary CIVO® microdosing platform in cutting-edge Phase 0 clinical trials to enable simultaneous evaluation of multiple drugs and combinations in the cancer patient’s own tumor. CIVO provides a detailed understanding of tumor response years earlier than the conventional approach, improving both the effectiveness and economics of cancer drug development.
Prolocor’s mission is to develop a diagnostic test that quantifies platelet FcγRIIa and identifies patients at high and low risk for heart attack, stroke, and death, enabling precision targeting of the right medicines for the right patients, at a net savings to the health system. This test has the potential to revolutionize the treatment of coronary patients globally.
TrakCel effectively and efficiently orchestrates the advanced therapy value chain – delivering a safe, scalable, and compliant solution. OCELLOS by TrakCel has been designed to streamline the orchestration of clinical and commercial stage therapies, ensuring Chain of Identity and Chain of Custody are managed at each step of the patient journey.
The Recovery Platform is an opioid treatment platform focused on retention and reduced relapse for Medication Assisted Treatment patients. The platform is seamlessly integrated with laboratories, state PDMPs, and EHRs and leverages state of the art technology, including concierge services such as telemedicine.
Vital exists to make diagnostics ubiquitous, moving healthcare beyond episodic encounters to a world of proactive and accessible care. In pursuit of this mission, Vital is building an ecosystem of devices, software & knowledge, including a platform to enable a broad panel of routine diagnostics in 20 minutes in primary care practices.